Itopride hydrochloride

Phase 3Small molecule

FForest Laboratories

Itopride hydrochloride is one of 19 small molecule programs targeting Dyspepsia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DyspepsiaCompleted

DyspepsiaPhase 3

Completed

Competition

Competitive Landscape

25 competitors in Dyspepsia

#DrugCompanyPhaseTrials

Prevacid

Takeda

Approved

3 2

Buspar

Bristol-Myers Squibb

Approved

1 3

Nexium

DDexcel Pharma Technologies Ltd.

Approved

6 4

Protonix

WWyeth-Lederle Vaccines

Approved

5 5

Prilosec

DDexcel Pharma Technologies Ltd.

Approved

4 6

Resotran

Pepcid

2 8

Pulmicort

SSalix

Approved

1 9

Osmitrol

BB. Braun Medical Inc.

Approved

1 10

Clostridium Butyricum

XXijing Hospital of Digestive Diseases

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dyspepsia4 trials

Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia

Active, not recruiting·AAbbott·Phase 3·NCT06217393·564 enrolled

Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal

Completed·FForest Laboratories·Phase 3·NCT00112177·500 enrolled

Long-term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia

Completed·FForest Laboratories·Phase 3·NCT00110968·300 enrolled

Show 1 more trial

Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal

Completed·FForest Laboratories·Phase 3·NCT00112190·645 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Itopride hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Itopride hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Itopride hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Forest Laboratories company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FForest Laboratories

Itopride hydrochloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dyspepsia4 trials

References

Drug Info

Quick Facts

Related News